Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus CORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus CORTONE.
ADVAIR DISKUS 250/50 vs CORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators. Salmeterol xinafoate is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
1 inhalation (fluticasone propionate 250 mcg and salmeterol 50 mcg) twice daily, approximately 12 hours apart, via oral inhalation.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
None Documented
None Documented
Fluticasone propionate: 14-17 hours (terminal). Salmeterol: 5.5 hours (terminal). The fluticasone half-life supports twice-daily dosing with potential accumulation.
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Fluticasone propionate: <5% renal (as metabolites), majority biliary/fecal. Salmeterol: 57% renal (as metabolites), 30% fecal.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid